Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 4/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23114832 | 0.87 | ACACB (0.50) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL25146910 | 0.87 | ACACB (0.50) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL23425828 | 0.85 | ACACB (0.43) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL23707108 | 0.83 | NPC1 (0.40) | CHRNB2CHRNA4SYKACKR3MGLL | |
| SCHEMBL23103163 | 0.82 | PRKDC (0.35) | ACACBCHRNB2CHRNA4PRKDCSYK | |
| SCHEMBL23107214 | 0.82 | PRKDC (0.35) | ACACBCHRNB2CHRNA4PRKDCSYK | |
| SCHEMBL23103154 | 0.82 | PRKDC (0.35) | ACACBCHRNB2CHRNA4PRKDCSYK | |
| SCHEMBL23103159 | 0.82 | PRKDC (0.35) | ACACBCHRNB2CHRNA4PRKDCSYK | |
| SCHEMBL23103153 | 0.82 | PRKDC (0.35) | ACACBCHRNB2CHRNA4PRKDCSYK | |
| SCHEMBL23089168 | 0.82 | PIK3CA (0.37) | CHRNB2CHRNA4PRKDCSYKHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | ACACB 2899/4885CHRNB2 1443/4885CHRNA4 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.